Sale of IP Assets for Nabi Biopharmaceuticals

Handled the intellectual property aspects of a $46 million deal between our client, Nabi Biopharmaceuticals, and GlaxoSmithKline, relating to the sale of a vaccine against S. aureus, which will be critical in the fight against the multidrug-resistant bacterium known as MRSA.